¹²⁵I brachytherapy combined with chemotherapy of advanced non-small cell lung cancer

Subjects: Nuclear Science and Technology >> Nuclear Materials and Techniques submitted time 2023-06-18 Cooperative journals: 《Nuclear Science and Techniques》

LIN Yuan-Qiang SUN Yu WANG Ren-Jie GAO Shi CHEN Bin SUN Bu-Tong MA Qing-Jie JI Tie-Feng ZHANG Hai-Shan

Abstract： This study was to evaluate effect of ¹²⁵I brachytherapy combined with chemotherapy on advanced non-small cell lung cancer (NSCLC). Patients with NSCLC in stages III to IV were divided into two groups: Group A (n=27) received ¹²⁵I brachytherapy combined with gemcitabine and cisplatin (GP) chemotherapy, and Group B (n=27) received GP chemotherapy only. The results showed that the overall response rate and median progression-free survival time were 78% and 11.5 months in Group A, 41% and 8 months in Group B, respectively (P<0.05). For Group A, the 1- and 2-years survival rates were 67% and 37%, respectively, with the median survival time of 16 months, whereas the corresponding data of Group B were 48%, 22% and 11.5 months (P>0.05). The interventional complications in Group A included 5 patients with postoperative pneumothorax and 4 patients with hemoptysis. No patients had radiation pneumonia, radiation esophagitis or esophagotracheal fistula. Chemotherapy treatment-related toxicities were not significantly different between the two groups. The relief of tumor-associated symptoms including cough, hemoptysis, chest pain, and short breath was found in both groups, without statistical difference in remission rates between Groups A and B (P>0.05). In conclusion, ¹²⁵I brachytherapy combined with chemotherapy proved to be safe and effective for treating advanced NSCLC with few complications. It improves local control rate and prolongs the progression-free survival time.

YES

 Hits 1591  Downloads 246  Comment 0